Cargando…

Use of daratumumab in high risk multiple myeloma: A meta‐analysis

Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340 newly diagnosed MM patients (1982 with standard risk and 358 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Premkumar, Vikram, Pan, Samuel, Lentzsch, Suzanne, Bhutani, Divaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175911/
https://www.ncbi.nlm.nih.gov/pubmed/35847747
http://dx.doi.org/10.1002/jha2.47
_version_ 1784722549873049600
author Premkumar, Vikram
Pan, Samuel
Lentzsch, Suzanne
Bhutani, Divaya
author_facet Premkumar, Vikram
Pan, Samuel
Lentzsch, Suzanne
Bhutani, Divaya
author_sort Premkumar, Vikram
collection PubMed
description Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340 newly diagnosed MM patients (1982 with standard risk and 358 with high risk cytogenetics) and 673 patients with relapsed/refractory MM (513 with standard risk and 160 with high risk cytogenetics) to assess which cytogenetic subgroups derived PFS benefit from Daratumumab. Studies included were the CASSIOPEIA, MAIA and ALCYONE (for newly diagnosed MM) and the CASTOR and POLLUX trials (for relapsed/refractory MM). Daratumumab's addition led to a clear benefit in standard risk newly diagnosed MM (HR 0.43; 95% CI, 0.35‐0.53; P < .05) and both high and standard risk relapsed/refractory disease (HR 0.28; 95% CI, 0.21‐0.36; P < .05 and HR 0.48; 95% CI, 0.30‐0.76; P < .05, respectively). No clear benefit was seen in newly diagnosed high risk MM. These findings fail to demonstrate PFS benefit from Daratumumab's addition in high risk newly diagnosed MM. Data forthcoming from the GRIFFIN and MASTER trials may increase the power of the study and provide a definitive answer. Daratumumab remains important in standard risk upfront and relapsed/refractory MM and high risk relapsed/refractory MM.
format Online
Article
Text
id pubmed-9175911
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91759112022-07-14 Use of daratumumab in high risk multiple myeloma: A meta‐analysis Premkumar, Vikram Pan, Samuel Lentzsch, Suzanne Bhutani, Divaya EJHaem Short Reports Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340 newly diagnosed MM patients (1982 with standard risk and 358 with high risk cytogenetics) and 673 patients with relapsed/refractory MM (513 with standard risk and 160 with high risk cytogenetics) to assess which cytogenetic subgroups derived PFS benefit from Daratumumab. Studies included were the CASSIOPEIA, MAIA and ALCYONE (for newly diagnosed MM) and the CASTOR and POLLUX trials (for relapsed/refractory MM). Daratumumab's addition led to a clear benefit in standard risk newly diagnosed MM (HR 0.43; 95% CI, 0.35‐0.53; P < .05) and both high and standard risk relapsed/refractory disease (HR 0.28; 95% CI, 0.21‐0.36; P < .05 and HR 0.48; 95% CI, 0.30‐0.76; P < .05, respectively). No clear benefit was seen in newly diagnosed high risk MM. These findings fail to demonstrate PFS benefit from Daratumumab's addition in high risk newly diagnosed MM. Data forthcoming from the GRIFFIN and MASTER trials may increase the power of the study and provide a definitive answer. Daratumumab remains important in standard risk upfront and relapsed/refractory MM and high risk relapsed/refractory MM. John Wiley and Sons Inc. 2020-07-02 /pmc/articles/PMC9175911/ /pubmed/35847747 http://dx.doi.org/10.1002/jha2.47 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Premkumar, Vikram
Pan, Samuel
Lentzsch, Suzanne
Bhutani, Divaya
Use of daratumumab in high risk multiple myeloma: A meta‐analysis
title Use of daratumumab in high risk multiple myeloma: A meta‐analysis
title_full Use of daratumumab in high risk multiple myeloma: A meta‐analysis
title_fullStr Use of daratumumab in high risk multiple myeloma: A meta‐analysis
title_full_unstemmed Use of daratumumab in high risk multiple myeloma: A meta‐analysis
title_short Use of daratumumab in high risk multiple myeloma: A meta‐analysis
title_sort use of daratumumab in high risk multiple myeloma: a meta‐analysis
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175911/
https://www.ncbi.nlm.nih.gov/pubmed/35847747
http://dx.doi.org/10.1002/jha2.47
work_keys_str_mv AT premkumarvikram useofdaratumumabinhighriskmultiplemyelomaametaanalysis
AT pansamuel useofdaratumumabinhighriskmultiplemyelomaametaanalysis
AT lentzschsuzanne useofdaratumumabinhighriskmultiplemyelomaametaanalysis
AT bhutanidivaya useofdaratumumabinhighriskmultiplemyelomaametaanalysis